Cancer

Sep 10, 2025

Pathology—the discipline of diagnosing disease through tissue analysis, has long depended on glass slides and microscopes. Today, digital pathology is undergoing a remarkable shift, as whole-slide imaging (WSI) and artificial intelligence (AI) come together to streamline lab workflows, accelerate diagnoses, and enh...

Sep 09, 2025

NeuroNOS Secures FDA Orphan Drug Designation for BA-101 in Glioblastoma NeuroNOS, a biopharmaceutical company specializing in neurological disorders and neuro-oncology and a subsidiary of Beyond Air, announced that the FDA has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for...

Aug 01, 2025

The field of gene regulation and molecular medicine has witnessed a revolutionary advancement with the development of small interfering RNA (siRNA) therapeutics. Also known as short interfering RNA, siRNA is a class of double-stranded RNA molecules that plays a pivotal role in RNA interference (RNAi)—a cellular mec...

Jul 30, 2025

Immunohistochemistry has become an essential tool in both clinical and research settings, bridging the gap between molecular biology and histopathology. By combining immunology and histological techniques, it enables scientists and healthcare professionals to uncover intricate biological patterns and diagnose compl...

Jul 29, 2025

Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency Ascendis Pharma A/S announced that the FDA has approved SKYTROFA (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). Already approved for pediatric GHD since 2021, SKYTROFA is a once-weekly prodrug of ...

Jul 06, 2025

Nanobots in medicine and healthcare represent one of the most promising frontiers in modern science, poised to revolutionize diagnosis, treatment, and patient monitoring at a molecular level. These microscopic machines, often referred to as nanobots, nanorobots, or medical nanobots, are engineered to operate within...

Jun 24, 2025

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma Incyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the f...

Jun 18, 2025

Heart disease continues to be a major global health concern, impacting countless lives and placing a significant burden on healthcare systems worldwide. According to the World Health Organization, cardiovascular diseases are responsible for approximately 17.9 million deaths each year, accounting for nearly one-thir...

Jun 11, 2025

Buckle up, because the world of AI healthcare startups is on fire! Investors are throwing serious cash, think billions, at companies using artificial intelligence to shake up the pharmaceutical industry. Over the past decade, a jaw-dropping USD 60 billion has flooded into AI healthcare startups, with USD 30 billion...

May 20, 2025

Incyte’s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval incl...